Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern

We note with great concern, the recently initiated LIGHTHOUSE trial (NCT04649060) for multiple myeloma (MM) and highlight here issues with the control arm and lack of equipoise in this clinical trial. Although this trial recently paused enrollment because of new data regarding a previous clinical trial (OCEAN, NCT03151811) involving melfufen flufenamide (melflufen), there are many important lessons in trial design, equipoise and drug development...